![Jenny Davies](/_next/image?url=https%3A%2F%2Fbrandconnect.gowlingwlg.com%2Fm%2F33691103b26e7461%2Foriginal%2FJenny-Davies.webp&w=3840&q=75)
Bio
Jenny Davies provides strategic advice to help her clients protect and exploit their R&D investment in the life sciences sector, medical device sector and the chemical industry. She negotiates agreements to support her clients' research, development, manufacture and commercialisation, and protects their markets through the enforcement of patents.
Jenny is a life sciences and patent specialist in Gowling WLG's Intellectual Property team. Her first class Masters in Biochemistry from Oxford University, 12 years' experience working across the life sciences sector and personal touch enable her to build strong relationships with her clients to get to the heart of their business and the commercial and technical challenges they face.
Jenny delivers business-focused solutions across her unique practice area spanning patents and dispute resolution, transactions ranging from strategic licensing to highly complex collaborations and regulatory matters. Jenny advises clients in all aspects of patent enforcement, from technical analysis and global strategy to leading UK litigation and EPO oppositions.
Given the commercial and practical value of the assets Jenny protects, her approach combines precision and detail with a commercial mindset and sector-led solutions. Jenny has helped clients including AstraZeneca, BioNTech, GlaxoSmithKline, Heptares Therapeutics, Immunocore, MedImmune and Lundbeck. Clients praise her "endless determination", "formidable intellect" and are "deeply impressed" with her "unusual capacity to think creatively".
Jenny's work highlights include leading ground-breaking patent litigation up to the UK Court of Appeal to achieve a novel form of "Arrow declaration" for Fujifilm Kyowa Kirin and advising AstraZeneca across a range of high value and complex transactions: its collaboration with the University of Oxford (COVID-19 vaccine); two $6 billion oncology collaborations with Daiichi Sankyo; an $8.5 billion oncology deal with Merck; and a $300 million oncology deal with Genzyme (Caprelsa).
Jenny is a member of the BioIndustry Association's IP Advisory Committee, and SPC and exclusivities committee, and a regular speaker on patent litigation and strategy.